95 related articles for article (PubMed ID: 28300669)
21. A presumed case of Darbepoetin-induced myocardial infarction in the patient with MDS-RARS.
Zafar AA; Kouides P
Clin Case Rep; 2020 Apr; 8(4):658-660. PubMed ID: 32274030
[TBL] [Abstract][Full Text] [Related]
22. Cell signaling by protein carbonylation and decarbonylation.
Wong CM; Marcocci L; Liu L; Suzuki YJ
Antioxid Redox Signal; 2010 Mar; 12(3):393-404. PubMed ID: 19686045
[TBL] [Abstract][Full Text] [Related]
23. Myelodysplastic Syndromes and Modalities of Treatment: An Updated Literature Review.
Zamora DI; Patel GS; Grossmann I; Rodriguez K; Soni M; Joshi PK; Patel SC; Shreya D; Sange I
Cureus; 2021 Dec; 13(12):e20116. PubMed ID: 34873563
[TBL] [Abstract][Full Text] [Related]
24. Analyzing Blood Cells of High-Risk Myelodysplastic Syndrome Patients Using Interferometric Phase Microscopy and Fluorescent Flow Cytometry.
Barnea I; Luria L; Girsault A; Dabah O; Dudaie M; Mirsky SK; Merkel D; Shaked NT
Bioengineering (Basel); 2024 Mar; 11(3):. PubMed ID: 38534530
[TBL] [Abstract][Full Text] [Related]
25. Synthesis of New Bodipy Hydrazide Fluorescent Probes for the Detection of Carbonylated Proteins Generated by Oxidative Stress.
Nina-Diogo A; Hyzewicz J; Hamon MP; Forté J; Thorimbert S; Friguet B; Botuha C
Chembiochem; 2024 May; ():e202400093. PubMed ID: 38695553
[TBL] [Abstract][Full Text] [Related]
26. Protein Carbonylation as a Biomarker of Oxidative Stress and a Therapeutic Target in Neonatal Brain Damage.
Martínez-Orgado J; Martínez-Vega M; Silva L; Romero A; de Hoz-Rivera M; Villa M; Del Pozo A
Antioxidants (Basel); 2023 Oct; 12(10):. PubMed ID: 37891918
[TBL] [Abstract][Full Text] [Related]
27. New proposals of the WHO working group (2016) for the diagnosis of myelodysplastic syndromes (MDS): Characteristics of refined MDS types.
Strupp C; Nachtkamp K; Hildebrandt B; Giagounidis A; Haas R; Gattermann N; Bennett JM; Aul C; Germing U
Leuk Res; 2017 Jun; 57():78-84. PubMed ID: 28324772
[TBL] [Abstract][Full Text] [Related]
28. Infectious complications in patients with myelodysplastic syndromes: A review of the literature with emphasis on patients treated with 5-azacitidine.
Radsak M; Platzbecker U; Schmidt CS; Hofmann WK; Nolte F
Eur J Haematol; 2017 Aug; 99(2):112-118. PubMed ID: 28321924
[TBL] [Abstract][Full Text] [Related]
29. [Azacitidine therapy for low-risk myelodysplastic syndrome developing after solid organ transplantation].
Inoue H; Morita Y; Rai S; Kakutani H; Ohyama Y; Taniguchi Y; Tanaka H; Shimada T; Tatsumi Y; Ashida T; Matsumura I
Rinsho Ketsueki; 2017; 58(2):138-142. PubMed ID: 28321091
[TBL] [Abstract][Full Text] [Related]
30. Long-term follow-up of a retrospective comparison of reduced-intensity conditioning and conventional high-dose conditioning for allogeneic transplantation from matched related donors in myelodysplastic syndromes.
Martino R; Henseler A; van Lint M; Schaap N; Finke J; Beelen D; Vigouroux S; Alessandrino EP; Mufti GJ; Veelken JH; Bruno B; Yakoub-Agha I; Volin L; Maertens J; Or R; Leblond V; Rovira M; Kalhs P; Alvarez AF; Vitek A; Sierra J; Wagner E; Robin M; de Witte T; Kröger N
Bone Marrow Transplant; 2017 Aug; 52(8):1107-1112. PubMed ID: 28319072
[TBL] [Abstract][Full Text] [Related]
31. Abnormal ADVIA 2120i neutrophil cytogram in myelodysplastic syndrome.
Gibbs G
Int J Lab Hematol; 2017 Jun; 39(3):e84-e85. PubMed ID: 28304132
[No Abstract] [Full Text] [Related]
32. Clonal evolution in myelodysplastic syndromes.
da Silva-Coelho P; Kroeze LI; Yoshida K; Koorenhof-Scheele TN; Knops R; van de Locht LT; de Graaf AO; Massop M; Sandmann S; Dugas M; Stevens-Kroef MJ; Cermak J; Shiraishi Y; Chiba K; Tanaka H; Miyano S; de Witte T; Blijlevens NMA; Muus P; Huls G; van der Reijden BA; Ogawa S; Jansen JH
Nat Commun; 2017 Apr; 8():15099. PubMed ID: 28429724
[TBL] [Abstract][Full Text] [Related]
33. Enumerating bone marrow blasts from nonerythroid cellularity improves outcome prediction in myelodysplastic syndromes and permits a better definition of the intermediate risk category of the Revised International Prognostic Scoring System (IPSS-R).
Calvo X; Arenillas L; Luño E; Senent L; Arnan M; Ramos F; Pedro C; Tormo M; Montoro J; Díez-Campelo M; Blanco ML; Arrizabalaga B; Xicoy B; Bonanad S; Jerez A; Nomdedeu M; Ferrer A; Sanz GF; Florensa L
Am J Hematol; 2017 Jul; 92(7):614-621. PubMed ID: 28370234
[TBL] [Abstract][Full Text] [Related]
34. An exploratory clinical trial of bortezomib in patients with lower risk myelodysplastic syndromes.
Daher M; Hidalgo Lopez JE; Randhawa JK; Jabbar KJ; Wei Y; Pemmaraju N; Borthakur G; Kadia T; Konopleva M; Kantarjian HM; Hearn K; Estrov Z; Reyes S; Bueso-Ramos CE; Garcia-Manero G
Am J Hematol; 2017 Jul; 92(7):674-682. PubMed ID: 28370157
[TBL] [Abstract][Full Text] [Related]
35. Increase of DNA damage and alteration of the DNA damage response in myelodysplastic syndromes and acute myeloid leukemias.
Popp HD; Naumann N; Brendel S; Henzler T; Weiss C; Hofmann WK; Fabarius A
Leuk Res; 2017 Jun; 57():112-118. PubMed ID: 28359030
[TBL] [Abstract][Full Text] [Related]
36. Linking aberrant glycosylation of plasma glycoproteins with progression of myelodysplastic syndromes: a study based on plasmonic biosensor and lectin array.
Chrastinová L; Pastva O; Bocková M; Kovářová H; Ceznerová E; Kotlín R; Pecherková P; Štikarová J; Hlaváčková A; Havlíček M; Válka J; Homola J; Suttnar J
Sci Rep; 2023 Aug; 13(1):12816. PubMed ID: 37550349
[TBL] [Abstract][Full Text] [Related]
37. Protein Carbonylation and Lipid Peroxidation in Hematological Malignancies.
Rodríguez-García A; García-Vicente R; Morales ML; Ortiz-Ruiz A; Martínez-López J; Linares M
Antioxidants (Basel); 2020 Dec; 9(12):. PubMed ID: 33271863
[TBL] [Abstract][Full Text] [Related]
38. Protein Carbonylation in Patients with Myelodysplastic Syndrome: An Opportunity for Deferasirox Therapy.
Rodríguez-García A; Morales ML; Garrido-García V; García-Baquero I; Leivas A; Carreño-Tarragona G; Sánchez R; Arenas A; Cedena T; Ayala RM; Bautista JM; Martínez-López J; Linares M
Antioxidants (Basel); 2019 Oct; 8(11):. PubMed ID: 31652983
[TBL] [Abstract][Full Text] [Related]
39. A New Approach for the Diagnosis of Myelodysplastic Syndrome Subtypes Based on Protein Interaction Analysis.
Chrastinová L; Pastva O; Bocková M; Lynn NS; Šácha P; Hubálek M; Suttnar J; Kotlín R; Štikarová J; Hlaváčková A; Pimková K; Čermák J; Homola J; Dyr JE
Sci Rep; 2019 Sep; 9(1):12647. PubMed ID: 31477761
[TBL] [Abstract][Full Text] [Related]
40.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
